The emergence of spatial genomics has introduced new possi-bilities for studying structure–function relationships in neuropsy-chiatric disorders.Spatial transcriptomics allows the detection of thousands of genes simu...The emergence of spatial genomics has introduced new possi-bilities for studying structure–function relationships in neuropsy-chiatric disorders.Spatial transcriptomics allows the detection of thousands of genes simultaneously up to single-cell resolu-tion,providing the spatial location of gene transcriptional activ-ity within a tissue sample.Spatial genomics technologies are de-veloping rapidly,and many of them have been used to construct brain spatial genomics atlases.A brain spatial transcriptomic at-las is a map of the gene expression across brain regions in situ—i.e.,within their anatomical context—often at single-cell or near-single-cell resolution.The brain spatial genomics atlas has been constructed for a few species including mice and humans.展开更多
The recent publication by Mollaoglu et al.1 in Cell reveals an unexpected role for tumor derived IL4 in driving immunotherapy resistance in ovarian cancer(OvCa).This finding nominates the combination of immunotherapy ...The recent publication by Mollaoglu et al.1 in Cell reveals an unexpected role for tumor derived IL4 in driving immunotherapy resistance in ovarian cancer(OvCa).This finding nominates the combination of immunotherapy and IL4-signaling targeting strategies as a promising new approach for the treatment of advanced OvCa.Ovarian Cancer(OvCa)is the third most common gynecological malignant disease affecting women.2 It is often diagnosed at late stages and is characterized by heterogenous features with limited treatment options.Initial response to standard of care platinumbased chemotherapy combined with surgery is often followed by disease relapse and subsequent death of patients.Despite the recent success of immune checkpoint inhibition in different cancer entities,most OvCa patients do not benefit from immunotherapy-based treatment approaches.The responsiveness of ovarian tumors to immune checkpoint blockade(ICB)is thereby hindered by weak immunogenicity due to low mutational burden and an immune suppressive tumor microenvironment(TME)characterized by heterogenous immune cell infiltration.3 Still,functional evidence for key factors that govern cancer cellimmune cell interaction and drive immunotherapy resistance in OvCa remains limited.展开更多
文摘The emergence of spatial genomics has introduced new possi-bilities for studying structure–function relationships in neuropsy-chiatric disorders.Spatial transcriptomics allows the detection of thousands of genes simultaneously up to single-cell resolu-tion,providing the spatial location of gene transcriptional activ-ity within a tissue sample.Spatial genomics technologies are de-veloping rapidly,and many of them have been used to construct brain spatial genomics atlases.A brain spatial transcriptomic at-las is a map of the gene expression across brain regions in situ—i.e.,within their anatomical context—often at single-cell or near-single-cell resolution.The brain spatial genomics atlas has been constructed for a few species including mice and humans.
基金funded by the Deutsche Forschungsgemeinschaft(DFG,German Research Foundation,LE 3613/3-1).
文摘The recent publication by Mollaoglu et al.1 in Cell reveals an unexpected role for tumor derived IL4 in driving immunotherapy resistance in ovarian cancer(OvCa).This finding nominates the combination of immunotherapy and IL4-signaling targeting strategies as a promising new approach for the treatment of advanced OvCa.Ovarian Cancer(OvCa)is the third most common gynecological malignant disease affecting women.2 It is often diagnosed at late stages and is characterized by heterogenous features with limited treatment options.Initial response to standard of care platinumbased chemotherapy combined with surgery is often followed by disease relapse and subsequent death of patients.Despite the recent success of immune checkpoint inhibition in different cancer entities,most OvCa patients do not benefit from immunotherapy-based treatment approaches.The responsiveness of ovarian tumors to immune checkpoint blockade(ICB)is thereby hindered by weak immunogenicity due to low mutational burden and an immune suppressive tumor microenvironment(TME)characterized by heterogenous immune cell infiltration.3 Still,functional evidence for key factors that govern cancer cellimmune cell interaction and drive immunotherapy resistance in OvCa remains limited.
